Plain-English translation of NCT05915442 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether three new immunotherapy medications—, , and —work better when combined with radiation therapy (called SBRT) to treat men with prostate cancer that has spread to a small number of locations. The idea is that these medications help your immune system recognize and fight the cancer, while the radiation destroys the tumors directly.
When prostate cancer spreads to only a few spots, doctors have a real opportunity to control it with focused treatments. This trial exists because early research suggests that this medication combination might help radiation work better by 'waking up' your immune system to attack cancer cells that radiation alone might miss.
You likely qualify if…
You likely don't qualify if…
You would take two oral medications daily for 4 weeks, then undergo targeted radiation therapy (SBRT) to the cancer spots. About one week after radiation ends, you would start a third medication (), which is given by infusion. Throughout the trial, you would have regular blood tests, PSA measurements, and imaging scans to track how well the treatment is working and monitor for side effects. The study involves about 23 men and is designed to last approximately 6 months of active treatment, with follow-up visits afterward.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States